

Press Release

TRIAGENICS, INC.

Contact: Leigh Colby, TriAgenics, Inc
541.527.1800

FOR IMMEDIATE RELEASE
January 10, 2025

TRIAGENICS COMPLETES \$5 MILLION SERIES A-3 RAISE

Investors rally around the company's latest funding round for Zero3® TBA, a novel 3rd molar tooth bud ablation treatment and patented technology.

REDMOND, Ore. – TriAgenics, Inc., pioneer of a fully guided tooth bud ablation technology called Zero3 TBA, announced the successful completion of its Series A-3 funding round after reaching its \$5 million goal.

Zero3 TBA technology is designed to provide dentists with a one-minute, preventive-care treatment option for children that prevents the formation of 3rd molars. The purpose is to eliminate the need for surgical extraction and to ensure improved lifelong health profiles for all patients.

To date, TriAgenics has raised \$12.5 million through Series A offerings. CEO, Leigh Colby, D.D.S., says the latest round of investment will fund the organization as the U.S. Food and Drug Administration conducts a premarket review of the Zero3 TBA system. Funding will also be used to conduct premarket research. The company's goal is to introduce Zero3 TBA treatment to the U.S. market this year.

“For many general dentists, managing 3rd molars is the bane of their professional practice,” says Colby. “So, we believe 3TBA will be the new standard of care by 2030.”

Following FDA clearance, dentists will send patient CBCT and intraoral scans to TriAgenics, which will fabricate custom 3TBA kits and ship them to dentists to perform the one-minute treatment using TriAgenics' proprietary Zero3 technology.

TriAgenics believes Zero3 TBA treatment has massive market potential. Total expenditures associated with extracting 3rd molars and correcting problems these teeth cause is estimated to be worth nearly \$5 billion in the U.S. alone. TriAgenics estimates its total addressable market will be greater than \$2.5 billion annually in the U.S.

TriAgenics holds 33 U.S. and international patents that protect its treatment and technology across the U.S., Canada, Mexico, Australia, and Europe. The company expects additional international patents will issue this year, further establishing TriAgenics' global intellectual property position.

About TriAgenics

TriAgenics is a disruptive oral health care company that has pioneered the development of a one-minute treatment designed to prevent 3rd molars from ever forming. Based on extensive animal trials, TriAgenics' Zero3 TBA system is expected to eliminate all pain and complications normally associated with 3rd molar extraction. TriAgenics' mission is to provide dentists and their patients with a non-surgical alternative that has no painful recovery or need to miss work or school. For more information, please visit www.triagenics.com.